Receive our newsletter – data, insights and analysis delivered to you
March 2, 2010

St Jude Medical’s Trifecta Valve Approved

A Trifecta valve used to replace a patient's diseased, damaged or malfunctioning aortic heart valve, developed by St Jude Medical, has received CE Mark approval. The Trifecta valve controls blood flow from the heart to the rest of the body and performs like a natural heart valve.

By cms admin

A Trifecta valve used to replace a patient’s diseased, damaged or malfunctioning aortic heart valve, developed by St Jude Medical, has received CE Mark approval.

The Trifecta valve controls blood flow from the heart to the rest of the body and performs like a natural heart valve.

The valve has a tri-leaflet stented pericardial design, which offers hemodynamic performance, or nearly unobstructed blood flow, to mimic the flow of a natural, healthy heart as closely as possible.

The next-generation tissue valve design includes leaflets manufactured from pericardial tissue attached to the exterior of the valve stent.

The valve’s titanium stent is covered with pericardial tissue to allow tissue-to-tissue contact when the leaflets open and close.

The Trifecta valve’s durability includes proprietary tissue fixation and St Jude Medical’s patented Linx AC technology, an anticalcification treatment designed to reduce tissue mineralisation.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management